Discount sways U.K. cost gatekeeper on AstraZeneca’s ovarian cancer med Lynparza

Emily Wasserman

AstraZeneca scored a victory for its drug , as watchdog the National Institute for Health and Care Excellence did an about-face and recommended the med for some patients as long as the company offers a .

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS